No abstract
The objectives of this consultation were:
· to review and update WHO protocols for assessing the therapeutic efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in areas with intense transmission (WHO/MAL/96.1077) and in areas with low to moderate transmission;
· to review the draft guidelines for assessing the therapeutic efficacy of chloroquine for vivax malaria;
· to review the role of in vitro tests and current methods for detecting molecular markers in the surveillance of resistance to antimalarial drugs;
· to define the technical and operational elements needed for strengthening surveillance of drug resistance of both falciparum and vivax malaria at the country level.
The World Health Organization (WHO) would like to acknowledge with gratitude the contributions made by the preparation of this report by:
¨ Peter Bloland, Centers for Disease Control and Prevention, Atlanta, United States of America ¨ Umberto D'Alessandro, Institute of Tropical Medicine, Antwerp, Belgium ¨ Pascal Ringwald, Emerging Public Health Risks including Drug Resistance, Department of Communicable Disease Surveillance and Response, World Health Organization ¨ William Watkins, University of Liverpool, United Kingdom
Disease Category: Infectious disease
Disease Name: Malaria
Age Range: Unknown
Sex: Either
Nature of Intervention: Other
- Clinical experts
- Epidemiologists
- Researchers
- Statisticians
- Recommendations made
- Semi structured discussion
A consultation on monitoring antimalarial drug resistance. The consultation, which was jointly organized by Emerging Public Health Risks including Drug Resistance, Communicable Disease Surveillance and Response (CSR/EPH) and Roll Back Malaria (RBM), was held at WHO headquarters in Geneva from 3 to 5 December 2001.